Claims for Patent: 6,255,555

Summary for Patent: 6,255,555

Title:	Transgenic mouse expressing human fusin and human CD4
Abstract:	This invention provides a transgenic mouse capable of expressing at least two cell surface membrane proteins of human T lymphocytes, transgenes for use in production of the transgenic mouse, and a method for producing the transgenic mouse using the transgenes. The cell surface membrane proteins of human T lymphocytes are associated particularly with human immunodeficiency virus (HIV) infection, and are preferably human CD4 and fusin (CXCR4). The transgenic mouse is able to inherit to its progeny a trait of expressing the cell surface membrane proteins of human T lymphocytes, thus being useful for an animal model for HIV infection and AIDS.
Inventor(s):	Sawada; Shinichiro (Ibaraki, JP)
Assignee:	Japan Science and Technology Corporation (JP)
Application Number:	09/061,048
Patent Claims:	1. A transgenic mouse whose genome comprises: a first transgene comprising a transcriptional control region operably linked to cDNA encoding human fusin (CXCR4), wherein said control region comprises a murine CD4 promoter; a second transgene comprising a transcriptional control region operably linked to DNA encoding human CD4, wherein said control region comprises a CD4 promoter; and wherein said transgene comprises at least one member of the group consisting of a murine CD4 promoter and a modified human CD4 intron III; wherein the transgenes are co expressed on the surface of CD4+T lymphocytes. 2. The transgenic mouse of claim 1 wherein the first transgene further comprises a CD4 enhancer. 3. The transgenic mouse of claim 1 wherein the first transgene further comprises a CD4 silencer. 4. The transgenic mouse of claim 1 wherein the first transgene further comprises a CD4 enhancer and CD4 silencer. 5. The transgenic mouse of claim 1 wherein the first transgene comprises the murine CD4 enhancer, promoter, exon I, intron I, and part of exon II, as shown in Construct a of FIG. 1(a). 6. The transgenic mouse of claim 1 wherein the second transgene further comprises a CD4 enhancer. 7. The transgenic mouse of claim 1 wherein the second transgene further comprises a CD4 silencer. 8. The transgenic mouse of claim 1 wherein the second transgene further comprises a modified human CD4 intron III. 9. The transgenic mouse of claim 1 wherein the second transgene further comprises a CD4 enhancer, CD4 silencer, and a modified human CD4 intron III. 10. The transgenic mouse of claim 1 wherein the second transgene further comprises a human CD4 promoter, murine CD4 enhancer, human CD4 silencer, and a modified human CD4 intron III, as shown in Construct b of FIG. 1(b). 11. The transgenic mouse of claim 1 wherein the first and second transgenes are integrated into the same chromosome. 12. A transgene comprising a transcriptional control region operably linked to cDNA, encoding human fusin (CXCR4), wherein said control region comprises the murine CD4 promoter. 13. The transgene of claim 12 wherein said control region further comprises a CD4 enhancer. 14. The transgene of claim 12 wherein said control region further comprises a CD4 silencer. 15. The transgene of claim 12 wherein said control region further comprises a CD4 enhancer and CD4 silencer. 16. A transgene comprising a transcriptional control region operably linked to DNA encoding human CD4, wherein said control region comprises a CD4 promoter, a CD4 enhancer, a CD4 silencer, and a modified human CD 4 intron III. 17. A method for producing a transgenic mouse whose genome comprises human CD4 and human fusin comprising: a) injecting into a fertilized mouse egg: a transgene comprising a transcriptional control region operably linked to cDNA encoding human fusin (CXCR4), wherein said control region comprises the murine CD4 promoter; and a transgene comprising a transcriptional control region operably linked to DNA encoding human CD4, wherein said control region comprises the CD4 promoter; and wherein said transgene comprises at least one member of the group consisting of a murine CD4 promoter and a modified human CD4 intron III; b) transplanting the injected egg in a foster parent female mouse; c) selecting a mouse derived from an injected egg whose genome comprises human CD4 and human fusin, that coexpresses the human CD4 and human fusin on the surface of CD4+T lymphocytes.

Details for Patent 6,255,555

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-04-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-04-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-04-17